The QUT-administered BridgeTech Program is one of five organisations in the new $19.75M Clinical Translation and Commercialisation – Medtech program (CTCM) funded by the Australian Government’s Medical Research Future Fund through MTPConnect (Medtech and Pharma Growth Centre).
The CTCM program is a funding initiative to provide financial and educational support as well as infrastructure access to Australian small to medium-sized enterprises in medical device technology.
BridgeTech Program director QUT’s Distinguished Professor Lyn Griffiths said BridgeTech is a national professional development program that trains researchers and entrepreneurs to effectively navigate the medtech commercialisation journey.
“This partnership with CTCM symbolises strong endorsement in the future of Australian researchers and innovators,” Professor Griffiths said.
“We are excited to partner with MTPConnect through the CTCM program, and we’re looking forward to working with the other project partners to further commercialisation training skills in the medtech industry.
“Our program participants will take part in events, residential training, and online learning to develop a comprehensive understanding of the medtech commercialisation pathway,” she said.